American Headache Society (AHS) 61st Annual Scientific Meeting

CaMEO study highlights factors influencing opioid use in migraine

Roshini Claire Anthony, 20190902140202

Increasing body mass index (BMI), male sex, and certain comorbidities are factors associated with an elevated risk of opioid use in patients with migraine, according to results from the CaMEO* study presented at the recent American Headache Society conference (AHS 2019).

Migraine does not affect CVD risk in postmenopausal women

Roshini Claire Anthony, 20190828140303

A history of migraine does not appear to affect the risk of cardiovascular disease (CVD) in postmenopausal women, a large observational study presented at the American Headache Society conference (AHS 2019) showed.

Atogepant emerges as potential migraine prophylaxis

Roshini Claire Anthony, 20190822140503

Atogepant, a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist, has shown potential in prevention of migraine at a range of doses, according to a presentation at the recent American Headache Society conference (AHS 2019).

OnabotulinumtoxinA benefits patients with chronic migraine regardless of response status

Elaine Soliven, 20190822000000

Treatment with onabotulinumtoxinA significantly improves headache-related outcomes in patients with chronic migraine (CM) regardless of their response status, according to a study presented at AHS 2019.

OnabotulinumtoxinA a step FORWARD in preventing chronic migraine

Roshini Claire Anthony, 20190816140202

Patients receiving topiramate to prevent chronic migraines could potentially switch to onabotulinumtoxinA injections to reduce the frequency of their headaches, according to results of the FORWARD* study presented at the recent American Headache Society conference (AHS 2019).

Fremanezumab reduces migraine days

Elaine Soliven, 20190816000000

Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, significantly reduces the number of migraine days in patients with chronic migraine (CM) or episodic migraine (EM), according to the FOCUS* study presented at AHS 2019.

Yoga for migraine: Does it work?

Pearl Toh, 20190808180010

Incorporating yoga as a complementary therapy to standard pharmacological treatment of migraine helps reduce the frequency and intensity of migraine and its impact on the lives of people with such condition, according to the CONTAIN* study presented at the 2019 AHS Meeting.

Ubrogepant effective even in triptan-resistant migraine

Pearl Toh, 20190807190000

The novel small-molecule CGRP* receptor inhibitor ubrogepant was effective in relieving migraine pain and resolving the most bothersome migraine-associated symptom (MBS) regardless of prior triptan treatment, including in patients in whom triptans were ineffective, according to a pooled analysis of ACHIEVE I and II studies presented at AHS 2019.

Orally dissolving rimegepant confers rapid, sustained relief for migraine pain

Pearl Toh, 20190802190000

The small-molecule CGRP* receptor inhibitor rimegepant in orally disintegrating tablet (ODT) formulation provides rapid and sustained relief from an acute migraine attack with no safety concerns compared with placebo, according to a study presented at the recent AHS 2019 Meeting.

Mums with migraine likely to have colicky babies

Elvira Manzano, 20190801143000

Mums, but not dads, with migraine are more likely to have colicky babies, a large cross-sectional study finds.